Lenacapavir HIV prevention faces SA supply constraints

Lenacapavir HIV prevention could significantly shorten the time South Africa needs to bring HIV transmission under control. However, modelling suggests the country would need millions of people to receive the long-acting injection each year to realise its full potential. Clinical trials found that lenacapavir provided almost complete protection against HIV infection. The injectable prevention option could also address a persistent…

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in